Experts' opinion: Recommendations for retesting breast cancer metastases for HER2 and hormone receptor status

Frédérique Penault-Llorca, Renata A. Coudry, Wedad M. Hanna, Robert Y. Osamura, Josef Rüschoff, Giuseppe Viale

Research output: Contribution to journalArticle

Abstract

The human epidermal growth factor receptor 2 (HER2) and hormone receptor status of recurrent breast cancer may change between the tumor and metastases from negative to positive and vice versa, potentially affecting the treatment regimen. Retesting of metastases may therefore be crucial to allow appropriate selection of patients for whom targeted therapy is indicated; however, retesting is not routinely performed. This article recommends that metastases be retested for HER2 and hormone receptor status and provides practical guidance on when and how to retest, as agreed by a panel of expert pathologists with extensive experience of HER2 and hormone receptor testing.

Original languageEnglish
Pages (from-to)200-202
Number of pages3
JournalBreast
Volume22
Issue number2
DOIs
Publication statusPublished - Apr 2013

Keywords

  • Breast cancer
  • Estrogen receptors
  • HER2
  • Metastasis
  • Progesterone receptors
  • Re-biopsy

ASJC Scopus subject areas

  • Surgery

Fingerprint Dive into the research topics of 'Experts' opinion: Recommendations for retesting breast cancer metastases for HER2 and hormone receptor status'. Together they form a unique fingerprint.

  • Cite this